+Compare
CLGN
Stock ticker:
NASDAQ
AS OF
Aug 5 closing price
Price
$8.97
Change
+$0.72 (+8.73%)
Capitalization
91.46M

CLGN Price Prediction, CollPlant Biotechnologies Ltd AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Aug 05, 2022

Momentum Indicator for CLGN turns positive, indicating new upward trend

CLGN saw its Momentum Indicator move above the 0 level on August 01, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 117 similar instances where the indicator turned positive. In 95 of the 117 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLGN's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CLGN just turned positive on August 01, 2022. Looking at past instances where CLGN's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .

CLGN moved above its 50-day moving average on August 05, 2022 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLGN advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

CLGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CLGN entered a downward trend on July 27, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CLGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.269) is normal, around the industry mean (26.147). P/E Ratio (476.190) is within average values for comparable stocks, (101.357). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.698). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (86.207) is also within normal values, averaging (319.953).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

CLGN is expected to report earnings to fall 78.12% to -7 cents per share on September 23

CollPlant Biotechnologies Ltd CLGN Stock Earnings Reports
Q2'22
Est.
$-0.07
Q1'22
Missed
by $0.18
Q4'21
Beat
by $0.45
Q3'21
Missed
by $0.01
Q2'21
Missed
by $0.20
The last earnings report on May 26 showed earnings per share of -31 cents, missing the estimate of -14 cents. With 6.73K shares outstanding, the current market capitalization sits at 91.46M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.83B. The market cap for tickers in the group ranges from 2.5K to 240.53B. NONOF holds the highest valuation in this group at 240.53B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 176%. For the same Industry, the average monthly price growth was 178%, and the average quarterly price growth was -16%. LABFF experienced the highest price growth at 170,233%, while OTIC experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 55
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 12 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of medical devices

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4 Oppenheimer Street
Phone
+972 732325600
Employees
66
Web
https://www.collplant.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MGTX10.350.42
+4.23%
MeiraGTx Holdings plc
COUP76.500.84
+1.11%
Coupa Software
EGBN47.720.07
+0.15%
Eagle Bancorp
LLY301.32-4.47
-1.46%
Eli Lilly & Co
GOVX3.22-0.35
-9.80%
GeoVax Labs

CLGN and

Correlation & Price change

A.I.dvisor tells us that CLGN and GMDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLGN and GMDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLGN
1D Price
Change %
CLGN100%
+7.15%
GMDA - CLGN
31%
Poorly correlated
+10.77%
ATAI - CLGN
30%
Poorly correlated
+6.57%
MOR - CLGN
30%
Poorly correlated
+0.35%
AVEO - CLGN
29%
Poorly correlated
+0.52%
HOOK - CLGN
29%
Poorly correlated
+5.19%
More